232 related articles for article (PubMed ID: 23162092)
1. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Auriemma RS; Perone Y; Di Sarno A; Grasso LF; Guerra E; Gasperi M; Pivonello R; Colao A
J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
[TBL] [Abstract][Full Text] [Related]
2. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
3. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
5. Prolactinoma and pregnancy: From the wish of conception to lactation.
Maiter D
Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
8. Prolactinoma in pregnancy.
Molitch ME
Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
[TBL] [Abstract][Full Text] [Related]
9. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
10. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas, cabergoline, and pregnancy.
Glezer A; Bronstein MD
Endocrine; 2014 Sep; 47(1):64-9. PubMed ID: 24985062
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Araujo B; Belo S; Carvalho D
Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
[No Abstract] [Full Text] [Related]
13. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
14. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
[TBL] [Abstract][Full Text] [Related]
15. Management of prolactinomas during pregnancy.
Molitch ME
J Reprod Med; 1999 Dec; 44(12 Suppl):1121-6. PubMed ID: 10649822
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Ciccarelli E; Grottoli S; Razzore P; Gaia D; Bertagna A; Cirillo S; Cammarota T; Camanni M; Camanni F
J Endocrinol Invest; 1997 Oct; 20(9):547-51. PubMed ID: 9413809
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
18. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
Colao A; Abs R; Bárcena DG; Chanson P; Paulus W; Kleinberg DL
Clin Endocrinol (Oxf); 2008 Jan; 68(1):66-71. PubMed ID: 17760883
[TBL] [Abstract][Full Text] [Related]
20. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
